New opportunities for VACCINE RESEARCH

On the 1st of January 2019, Meilahti Vaccine Research Center (MeVac) started its operations in the Meilahti Campus, functioning as part of the HUS Helsinki University Hospital. MeVac collaborates closely with the University of Helsinki.

Professional staff implements research
The centre conducts both commissioned studies sponsored by pharmaceutical companies and academic investigator-initiated studies. The director of the unit is Anu Kantele, Professor of Infectious Diseases.

MeVac provides a site of conduct for vaccine studies with professional staff taking care of the initiation and implementation of studies. Clinical Research Institute HUCH is responsible for the applicable agreements and financial matters.

Vaccine research on special populations
HUS provides an ideal platform for carrying out vaccine studies because its population base consists of a major district covering 24 municipalities and regions of the Specific Catchment Area with 2.1 million inhabitants. The number of patients covered by HUS is the highest in our country and about half a million patients receive care in its various units every year.

In addition to patients of all ages, HUS also provides treatment for patients belonging to special populations, which is a good starting point for vaccine studies investigating immune defence in special populations. Moreover, the University Hospital is responsible for providing treatment for rare diseases and diseases requiring demanding care to patients living in the Expert Responsibility Area, which is larger than the hospital district, and in case of certain diseases, to patients in the entire country.
Individually planned patient recruitment
Both healthy individuals and patients belonging to special populations may be eligible to participate in studies. Various recruitment channels are available, including HUS patient register and outpatient departments, University of Helsinki, Population Register Centre and HUS personnel consisting of about 24,000 individuals. Subjects are recruited using methods specifically tailored to each study protocol.

Separate facilities in Biomedicum
The Vaccine Research Centre is situated in Biomedicum with a central location in the Meilahti Hospital area. The facilities have been designed for the conduct of clinical drug studies. They include three examination rooms, an office space, lockable storage spaces and a laboratory where blood sampling and processing can be carried out as applicable.

Contact us
We will be happy to answer your questions. For vaccine studies, please contact:

Director of MeVac,
Professor of Infectious Diseases
Anu Kantele
+358 50 427 0203

MeVac Physician-in-charge,
Adjunct Professor, Specialist in Otorhinolaryngology
Karin Blomgren
+358 50 427 1579

MeVac Research Nurse-In-Charge
Rauni Pakarinen
+358 50 311 6365

HUS.FI/MEVAC

Contractual matters:

Raimo Skottman
Head of Research Services
Clinical Research Institute HUCH Ltd
ext-raimo.skottman@hus.fi
+358 40 660 2290
MeVac began operating on 1st January 2019
At HUS Helsinki University Hospital more than half a million patients receive medical care annually. We have 25,000 professionals working for the best of all patients. We are responsible for providing specialized health care for the residents of our 24 member municipalities. In addition, the treatment of many rare and severe diseases is nationally centralized to HUS.

HUS is the biggest health care provider and the second largest employer in Finland. Our expertise is internationally recognized and accredited. As a university hospital, we continuously develop and evaluate our treatment methods and activities.